OBJECTIVE: Inducible expression of cyclooxygenase-2 (COX-2) and terminal prostaglandin synthases (tPGS) has been mainly analyzed in tumor, stromal, and inflammatory cells, and little is known about the regulation of prostanoid biosynthesis by endothelial cells. Here we characterize the profile of prostanoids produced by activated HUVECs and analyze the expression and activities of tPGS. METHODS AND RESULTS: Enzyme immunoassays indicated increased endothelial prostanoid production after proangiogenic stimulation, but without parallel upregulation of tPGS. Endothelial prostanoid production instead depended on the induction of COX-2 and was abolished by COX-2 silencing or pharmacological inhibition. COX-2 is functionally coupled to prostacyclin and thromboxane synthases in HUVECs, but these cells show no detectable PGE(2) synthase (PGES) activity. Endothelial PGE(2) production is partly mediated by nonenzymatic decomposition of COX-2-derived PGH(2), but endothelial-produced PGH(2) can also be metabolized enzymatically by microsomal PGES-1 in cocultured tumor cells. CONCLUSIONS: Our findings identify a novel transcellular metabolism of PGE(2) between the endothelial and tumor compartments. Given the role of PGE(2) as a mediator of COX-2 proangiogenic effects, transcellular metabolism of endothelial-derived PGH(2) is a potential target for treatment of pathological angiogenesis.
OBJECTIVE: Inducible expression of cyclooxygenase-2 (COX-2) and terminal prostaglandin synthases (tPGS) has been mainly analyzed in tumor, stromal, and inflammatory cells, and little is known about the regulation of prostanoid biosynthesis by endothelial cells. Here we characterize the profile of prostanoids produced by activated HUVECs and analyze the expression and activities of tPGS. METHODS AND RESULTS: Enzyme immunoassays indicated increased endothelial prostanoid production after proangiogenic stimulation, but without parallel upregulation of tPGS. Endothelial prostanoid production instead depended on the induction of COX-2 and was abolished by COX-2 silencing or pharmacological inhibition. COX-2 is functionally coupled to prostacyclin and thromboxane synthases in HUVECs, but these cells show no detectable PGE(2) synthase (PGES) activity. Endothelial PGE(2) production is partly mediated by nonenzymatic decomposition of COX-2-derived PGH(2), but endothelial-produced PGH(2) can also be metabolized enzymatically by microsomal PGES-1 in cocultured tumor cells. CONCLUSIONS: Our findings identify a novel transcellular metabolism of PGE(2) between the endothelial and tumor compartments. Given the role of PGE(2) as a mediator of COX-2 proangiogenic effects, transcellular metabolism of endothelial-derived PGH(2) is a potential target for treatment of pathological angiogenesis.
Authors: Cristina Correia; Sarindr Bhumiratana; Rui A Sousa; Rui L Reis; Gordana Vunjak-Novakovic Journal: Tissue Eng Part A Date: 2013-01-31 Impact factor: 3.845
Authors: Caroline Subra; David Grand; Karine Laulagnier; Alexandre Stella; Gérard Lambeau; Michael Paillasse; Philippe De Medina; Bernard Monsarrat; Bertrand Perret; Sandrine Silvente-Poirot; Marc Poirot; Michel Record Journal: J Lipid Res Date: 2010-04-27 Impact factor: 5.922
Authors: Karin Larsson; Anna Kock; Helena Idborg; Marie Arsenian Henriksson; Tommy Martinsson; John I Johnsen; Marina Korotkova; Per Kogner; Per-Johan Jakobsson Journal: Proc Natl Acad Sci U S A Date: 2015-06-15 Impact factor: 11.205
Authors: Na N Guan; Karl Svennersten; Petra J de Verdier; N Peter Wiklund; Lars E Gustafsson Journal: Br J Pharmacol Date: 2015-06-26 Impact factor: 8.739
Authors: Hiromi Hanaka; Sven-Christian Pawelzik; John Inge Johnsen; Marija Rakonjac; Kan Terawaki; Agnes Rasmuson; Baldur Sveinbjörnsson; Martin C Schumacher; Mats Hamberg; Bengt Samuelsson; Per-Johan Jakobsson; Per Kogner; Olof Rådmark Journal: Proc Natl Acad Sci U S A Date: 2009-10-21 Impact factor: 11.205